Imspex Diagnostics Ltd today announced that it has received CE mark for its BreathSpec® instrument for the detection of COVID-19 using non-invasive breath testing and analysis having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). BreathSpec®’s intended use is for the diagnosis of respiratory tract infections with specific utility for SARS-CoV-2 (Covid-19) in a Point of Care setting by clinicians and non-technical users. In collaboration with University Hospitals of Leicester NHS Trust, University of...